WAUKEGAN, Ill.--(BUSINESS WIRE)--May 30, 2006--NeoPharm, Inc. (Nasdaq:NEOL - News) today announced that patient enrollment has commenced in a multi-center Phase II clinical trial of LE-SN38 in the treatment of patients with metastatic colorectal cancer. The trial is being conducted by Cancer and Leukemia Group B (CALGB), an oncology clinical research group sponsored by the National Cancer Institute (NCI).
